Business
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chie
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7DDSqhC8eFJz3b_vK.hWvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUx/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – ","length":161,"tagName":"p"},{"type":"text","content":"– Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program –","length":169,"tagName":"p"},{"type":"text","content":"– Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% –","length":135,"tagName":"p"},{"type":"text","content":"– Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience –","length":125,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced its financial results for the full year ended December 31, 2025, and provided a business update.","length":388,"tagName":"p"},{"type":"text","content":"“We’ve advanced the ABP-450 program with a positive FDA meeting and supportive initial comparative analytical results that reinforce our biosimilar development strategy,” said Robert Bancroft, President and Chief Executive Officer of AEON. “The Agency’s feedback supports AEON’s proposed framework for completing our analytical program and preparing for our next regulatory interaction. At the same time, we strengthened our balance sheet through our recent financing and note exchange, positioning the Company to execute this next stage of development. With strong foundational biosimilarity...